For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole ...

Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...

Roger E Susi, CEO at iRadimed (NASDAQ: IRMD ), disclosed an insider sell on December 22, according to a recent SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and ...

The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with ...

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for CD20xCD3 bispecific Lunsumio VELO ...

Patients who depend on antibody drugs often spend long hours in infusion centers. These medicines are vital for treating many ...

Unfortunately, my experience is all too common. If you find yourself in a situation like I did, here's what you should do.

Access to cancer care in India is hindered by late diagnoses and a lack of specialised facilities. Efforts are underway to ...

Detailed price information for Baxter International Inc (BAX-N) from The Globe and Mail including charting and trades.

HC upheld Section 10A deduction after finding that STP unit was a new undertaking with fresh investment and infrastructure. It ruled that unit was not formed by splitting up or reconstruction of an ...

UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK ...